This page shows the latest gram-negative bacteria news and features for those working in and with pharma, biotech and healthcare.
negative bacteria. ... plus metronidazole treatment arm who had infections due to confirmed MBL-producing gram-negative bacteria were cured, versus 0% of those on best available therapy.
Fabimycin demonstrated the potential to infiltrate the defences of gram-negative bacteria and treat infections, while leaving other helpful microbes intact. ... Gram-negative bacteria are a class of microbes that infect millions of people worldwide,
The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Fetcroja was launched in the UK in
Therapeutic indicated to treat infections caused by Gram-negative bacteria. MSD (also known as Merck &Co) has launched its novel antibiotic combination Recarbrio in the UK. ... In a pivotal phase 3 trial of adult patients with infections caused by
The APEKS-NP study evaluated Fetcroja in severely ill patients with hospital-acquired, ventilator-associated or healthcare-associated pneumonia caused by a broad range of Gram-negative bacteria. ... Fetcroja launched in the UK in September, launching as
aerobic Gram-negative bacteria in adults. ... all Gram-negative pathogens considered to be of 'critical priority' by the World Health Organization.
More from news
Approximately 0 fully matching, plus 21 partially matching documents found.
using Warp's SMART and genome mining platforms for the discovery of oncology therapeutics and antibiotics targeting Gram negative bacteria.
270. Discuva / Roche. Collaboration. Antibiotics to target multi-drug resistant Gram negative bacteria.
BATON studies in colorectal cancer and metastatic triple negative breast cancer. ... In the meantime, Roche's pRED group will make use of Discuva's development technology, which uses gene sequencing and bioinformatics to identify targets for multi-drug
This combined intravenous therapy is currently undergoing phase III clinical trials as a potential first-line treatment for complicated intra-abdominal and urinary tract infections caused by certain Gram-negative bacteria, ... Astellas Pharma/ Cubist
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
No results were found
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...